ASCO 2022 Conference Coverage
Playback speed
10 seconds
ASCO 2022 Three-Year Outcomes and Correlative Analyses in Patients With NSCLC and a Very High PD-L1 Tumor Proportion Score ≥ 90% Treated With 1L Pembrolizumab
By
ASCO 2022 Conference Coverage
FEATURING
Biagio Ricciuti
By
ASCO 2022 Conference Coverage
FEATURING
Biagio Ricciuti
319 views
June 8, 2022
Comments 0
Login to view comments.
Click here to Login
Lung